Category: Oncology

Erlotinib (Management of Resistance) The development of second- and third-generation EGFR inhibitors, such as afatinib and Osimertinib, aims to overcome resistance to first-generation TKIs like erlotinib. These newer agents can target common resistance mutations and offer additional treatment options for patients.

Erlotinib (Resistance) Primary Resistance: Some patients with EGFR-mutant NSCLC may have intrinsic resistance to erlotinib due to additional mutations or alternative signaling pathways. Acquired Resistance: Over time, many patients develop resistance to erlotinib, often due to secondary mutations in the EGFR gene (such as T790M) or activation of alternative pathways (such as MET amplification)

Erlotinib (Side Effects) Common side effects of erlotinib include: Skin Rash: Acneiform rash is one of the most common and noticeable side effects. Diarrhea: Another frequently reported adverse effect. Fatigue: Patients may experience significant tiredness. Nausea and Vomiting: These gastrointestinal symptoms can also occur​

Erlotinib (NSCLC) Non-Small Cell Lung Cancer: Erlotinib is used for the treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. It is often prescribed as a first-line treatment in these cases​​. It can also be used as maintenance therapy for patients whose disease has […]

Osimertinib (Safety and Side Effects) Common Side Effects: Include diarrhea, rash, dry skin, nail toxicity, and stomatitis. These are generally manageable and similar to other EGFR TKIs. Serious Adverse Effects: Rare but serious adverse effects include interstitial lung disease (ILD), cardiomyopathy, and QT prolongation. Monitoring and management strategies are necessary to mitigate these risks​

Osimertinib (Clinical Trials and Efficacy) FLAURA Trial: A pivotal Phase III clinical trial that demonstrated osimertinib’s superiority over first-generation EGFR TKIs in terms of progression-free survival (PFS) and overall survival (OS) in the first-line setting​. AURA3 Trial: This trial showed significant improvement in PFS for patients with T790M-positive NSCLC treated with osimertinib compared to those […]